Clinical trial
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With…
NCT00078234 · Genta Incorporated, Industry · Completed
Key facts
| NCT number | NCT00078234 |
|---|---|
| Title | Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia |
| Official title | A Pilot Study of Genasense® (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia |
| Lead sponsor | Genta Incorporated, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Lymphocytic Leukemia |
| Intervention type | Drug |
| Interventions | Oblimersen-rituximab-fludarabine |
| Enrollment | 25 |
| Start date | Nov 1, 2003 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2010 |
| First posted | Feb 23, 2004 |
| Last update posted | Nov 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: